Who are Adefovir tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Therapeutic entecavir, Adefovir Dipivoxil Tablets, Adefovir dipivoxil (adefovir), Switch to B/F/TAF, Tenofovir/Emtricitabine, DTG/3TC/ABC + ELV/COBI/FTC/TAF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adefovir-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Adefovir tablets — Competitive Intelligence Brief

Adefovir tablets (Adefovir tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor. Area: Infectious Disease.

phase 2 Nucleotide reverse transcriptase inhibitor HBV DNA polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Adefovir tablets (Adefovir tablets) — GlaxoSmithKline. Adefovir works by inhibiting the replication of the hepatitis B virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adefovir tablets TARGET	Adefovir tablets	GlaxoSmithKline	phase 2	Nucleotide reverse transcriptase inhibitor	HBV DNA polymerase
Therapeutic entecavir	Therapeutic entecavir	Taipei Veterans General Hospital, Taiwan	marketed	Nucleoside analog reverse transcriptase inhibitor (NRTI)	HBV DNA polymerase
Adefovir Dipivoxil Tablets	Adefovir Dipivoxil Tablets	Sun Yat-sen University	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase and DNA polymerase
Adefovir dipivoxil (adefovir)	Adefovir dipivoxil (adefovir)	Merck Sharp & Dohme LLC	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase / DNA polymerase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Tenofovir/Emtricitabine	Tenofovir/Emtricitabine	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor class)

GlaxoSmithKline · 2 drugs in this class
IlDong Pharmaceutical Co Ltd · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Jiangxi Kvvit Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adefovir tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/adefovir-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab